- Medicus Pharma entered a co-development and licensing agreement with Pfizer for the early-stage antibody-drug conjugate CD228V.
- Pfizer granted an exclusive worldwide license for the asset while retaining patent ownership and the option to fund future development.
- The financial terms include an upfront payment of USD 12 million, subsequent anniversary payments of USD 15 million, development funding of USD 2 million, and potential milestone payments exceeding USD 1 billion alongside low double-digit royalties.
